Tiêu đề 10.25 - 10.55 EN Paediatric hyperthyroidism - Vietnam CME - May 2025 Paediatric hyperthyroidism - Vietnam CME - May 2025.pptx ✅

Paediatric Hyperthyroidism Dr Tony Huynh MBBS PhD FRACP FRCPA Director – Endocrinology & Diabetes, Queensland Children’s Hospital Chemical Pathologist – Mater Pathology Paediatric Endocrinology CME Hanoi, Vietnam 31/05/2025
Queensland Children’s Hospital Brisbane, Queensland, Australia Gold Coast, Queensland, Australia Fellow School, 4 – 7 October 2026
Overview Causes of paediatric thyrotoxicosis Paediatric Graves’ Disease – age distribution Paediatric Graves’ Disease Epidemiology Treatment efficacy and complications Physiology of the fetal HPT axis Neonatal thyroid disorders and maternal Graves’ Disease Clinical implications of hyperthyroidism for the fetus and neonate Management of at-risk pregnancies and neonates
Autoimmune condition that results from the presence of TSH-receptor antibodies (TRAb; also known as thyrotropin binding inhibiting immunoglobulins, abbreviated as TBII) leads to an overactive thyroid gland (suppressed TSH, high FT4/FT3) TRAb act as an agonist of the TSH receptor, causing excessive thyroid hormone secretion and disruption of normal HPT regulation. pituitary control of the thyroid TRAb can be stimulating, neutral or blocking TRAb can initially be negative with biochemical evidence of hyperthyroidism Also important to measure TPO and anti-thyroglobulin as may be hyperthyroid phase of Hasmimoto’s thyroiditis Rare in children Incidence of 4.58/100 000 per year, incidence is even lower in < 15 years (1 to 2.91/100 000 per year) Incidence in children less than 5 years is about 10-fold less than those older than 10 years Only approximately 5% of all GD patients have their onset during childhood Introduction Mooij CF et al. JCEM 2025; 110: e878–e885 Rivkees SA. 2022; 107: 3408–3417